Intermittency

NexTech Solutions Powers the Future of Edge Infrastructure Deployment with MANTLE Automation Platform

Retrieved on: 
Wednesday, February 16, 2022
Cloud, Soldier, JSON, Department, VMware ESXi, Department of Defense Architecture Framework, VP, NTS, United States Department of Defense, Solution, Intermittency, View, Automation, H/W, Multimedia, Renewable energy, Limited, Engineering

MANTLE automatically provisions infrastructure components, deploys modern workloads, and verifies the integrity of the configuration before safely shutting down and preparing for deployment.

Key Points: 
  • MANTLE automatically provisions infrastructure components, deploys modern workloads, and verifies the integrity of the configuration before safely shutting down and preparing for deployment.
  • "MANTLE makes your IT infrastructure deployment faster, safer, and smarter," said Will Lester, VP of Engineering, NTS.
  • MANTLE helps make the Modern Deployable Edge a reality by significantly reducing deployment effort and ensuring the kit is built to spec on-time, every time.
  • NexTech Solutions is focused on systems and network engineering to support cloud, hybrid, and edge solutions.

Global Cardiovascular Partnering Report 2014-2021: Deal Trends, Players and Financials of 850 Deals - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 11, 2022
Health, Cardiology, Shortness of breath, Cardiogenic shock, Research, Technology, Peripheral artery disease, Abdominal aortic aneurysm, Heart failure, Birth defect, Marfan syndrome, Confidentiality, Congestion, Myocardial infarction, Long QT syndrome, Ductus arteriosus, Intellectual property, Fatigue, Varicose veins, Intermittency, Finance, Atrial fibrillation, Congenital heart defect, Syndrome, Ventricular tachycardia, Ownership, Cardiovascular disease, Aortic stenosis, Circulatory system, Peripheral, Players, Coronary artery disease, Ventricular fibrillation, Chest pain, Supraventricular tachycardia, Valvular heart disease, Video game, Pharmaceutical industry, Lease, Sales, Petroleum, Property management, Practice of law, Restenosis, Thrombus, Hypertension, Hypercholesterolemia, Cardiomyopathy, Arrhythmia, Global, Atherosclerosis, Angina

The "Global Cardiovascular Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cardiovascular Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 850 cardiovascular deals.
  • The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.
  • In Global Cardiovascular Partnering 2014-2021: Deal trends, players and financials, the available deals are listed by:
    Analyzing actual contract agreements allows assessment of the following:
    What are the precise rights granted or optioned?

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

Retrieved on: 
Friday, September 17, 2021
Intermittency, Ovarian cancer, Food, Patient, Lists of diseases, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Goal, Pancreatic cancer, Intellectual property, Intention, Comparator, COVID-19, Pharmaceutical industry

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors.

Key Points: 
  • Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian, adrenal and castration-resistant prostate cancer and Cushings syndrome.
  • Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents.
  • In this press release, forward-looking statements, include those concerning the clinical attributes of relacorilant and its potential benefits in patients with ovarian cancer, results of our Phase 2 trial and our planning for a Phase 3 pivotal trial.

Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021

Retrieved on: 
Monday, September 13, 2021
Pharmaceutical, Genetics, Health, Clinical Trials, Arsenic trioxide, Ovarian cancer, 2021 Essex County Council election, Patient, ID, Poster, PD, Investor, Syros, CDK7, Gene, ESMO, Genome, RARA, Intermittency, Safety, NASDAQ, Breast, Acute myeloid leukemia, KRAS, Histology, Acute promyelocytic leukemia, Webcast, Lung, Pharmaceutical industry

The oral presentation will include safety, tolerability, and initial clinical activity data for SY-5609 in patients with breast, colorectal, lung, ovarian and pancreatic cancers, as well as in patients with solid tumors of any histology harboring Rb pathway alterations.

Key Points: 
  • The oral presentation will include safety, tolerability, and initial clinical activity data for SY-5609 in patients with breast, colorectal, lung, ovarian and pancreatic cancers, as well as in patients with solid tumors of any histology harboring Rb pathway alterations.
  • The abstract for the oral presentation on the Phase 1 dose-escalation data will remain embargoed until September 17 at 00:05 CEST (September 16 at 6:05 p.m.
  • ET to discuss the new clinical and preclinical data for SY-5609, which will be presented at the ESMO Congress 2021.
  • A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com .

Global Industry Analysts Predicts the World Environmental Sensing and Monitoring Technologies Market to Reach $25.1 Billion by 2026

Retrieved on: 
Thursday, September 2, 2021
GIA, Temperature, COVID-19, Central Statistics Office (India), Hach Company, SAN, Connected space, Location identifier, CAGR, Biophysical environment, Marketing, Internet, Passive monitoring, City Technology College, Agilent Technologies, Integrated Biological Detection System, Northrop Grumman, Forecasting, Danaher Corporation, Players, Component, Raytheon Company, Noise measurement, Continuous monitoring, Research, Geography, Growth, Intermittency, TE, Soil, Lockheed Martin, Intelligence, Renewable energy

SAN FRANCISCO, Sept. 2, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Environmental Sensing and Monitoring Technologies - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Sept. 2, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Environmental Sensing and Monitoring Technologies - Global Market Trajectory & Analytics" .
  • Companies:87 - Players covered include Agilent Technologies, Inc.; AirTest Technologies Inc.; Applied Technologies Inc.; ChemTreat; City Technology Ltd.; Coastal Environmental Systems Inc.; Danaher Corporation; E.S.I.
  • The U.S. Market is Estimated at $5.2 Billion in 2021, While China is Forecast to Reach $5.2 Billion by 2026
    The Environmental Sensing and Monitoring Technologies market in the U.S. is estimated at US$5.2 Billion in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Global Intermittent Urinary Catheters Market to 2026: Teleflex, Cardinal Health and Coloplast at the Forefront - ResearchAndMarkets.com

Retrieved on: 
Friday, August 20, 2021
Health, Medical Supplies, Medical Devices, Cardiac catheterization, CAGR, Competitive landscape, Prevalence, Intermittency, Review, CAUTI, PEST analysis, United Kingdom, Lists of diseases, MM, Catheter-associated urinary tract infection, Catheter, Multiple sclerosis, Medical imaging, Public relations

This 'Intermittent Urinary Catheters Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of intermittent urinary catheters and the historical and forecasted intermittent urinary catheters market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan.

Key Points: 
  • This 'Intermittent Urinary Catheters Market Insights, Competitive Landscape and Market Forecast-2026' report delivers an in-depth understanding of intermittent urinary catheters and the historical and forecasted intermittent urinary catheters market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan.
  • The Intermittent Urinary Catheters market report provides an overview of intermittent urinary catheters, applications of intermittent urinary catheters as well as its PEST Analysis.
  • Additionally, the report provides insight on the intermittent urinary catheters market share of the individual intermittent urinary catheters, current and forecasted intermittent urinary catheters market size from 2018 to 2026, segmented by seven major markets.
  • Additionally, an all-inclusive account of the currently available intermittent urinary catheters is provided, which will have an impact on the future market of intermittent urinary catheters.